PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.43
D/E ratio 0.3-0.5 - Conservative leverage that Benjamin Graham would endorse. Verify if Current Ratio confirms strong liquidity position.
0.83
Net debt under 1x EBITDA - Very conservative position that Benjamin Graham would endorse. Consider examining Interest Coverage to confirm strong debt service capacity.
No Data
No Data available this quarter, please select a different quarter.
1.45
Current ratio 1.2-1.5 - Adequate liquidity that Peter Lynch might accept. Cross-check Interest Coverage to ensure overall financial health.
No Data
No Data available this quarter, please select a different quarter.